Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by skibum45on Aug 05, 2019 1:15am
190 Views
Post# 29993708

RE:RE:RE:Newbie

RE:RE:RE:NewbieNumbers from Sedi ...
    Common Shares Options (Common Shares) Restricted Share Units (Common Shares) Warrants (Common Shares)
Bourgeois, Nicole 4,272,250 500,000 600,000  
Brouard, Eric 79,000   175,000  
Buret,Andre 210,000      
Curtis, Scott 320,000 850,000 730,000 33,000
Flower, Roderick 212,492 487,508 360,000  
Khouri, Amal     360,000  
Legault, Daniel        
  Direct 265,000 5,130,206 4,750,000 40,000
  Schmed Enterprises 296,666      
Macnee, Walter 4,390,267 525,000 360,000  
McMillan, Michael 4,272,520 500,000 600,000  
Vaughan, David 55,000 810,000 550,000  
Wallace, John        
  Direct 276,770 5,600,000 4,200,000  
  AltaPharm Intl 625,000      
Wilson, Alain        
  Direct   900,000 1,100,000  
  The Elegen Group Inc. 38,100      
Wu, Yung Cheng        
  Direct 1,500,000 200,000 360,000  
  NFQ Ventures Ltd. 1,900,000     500,000
           
TOTALS: 18,713,065 15,502,714 14,145,000 573,000

Bullboard Posts